WO2022250416A1 - 리포펩타이드와 폴리(i:c) 아쥬번트를 이용하는 면역항암치료제 조성물 - Google Patents
리포펩타이드와 폴리(i:c) 아쥬번트를 이용하는 면역항암치료제 조성물 Download PDFInfo
- Publication number
- WO2022250416A1 WO2022250416A1 PCT/KR2022/007348 KR2022007348W WO2022250416A1 WO 2022250416 A1 WO2022250416 A1 WO 2022250416A1 KR 2022007348 W KR2022007348 W KR 2022007348W WO 2022250416 A1 WO2022250416 A1 WO 2022250416A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- poly
- cancer
- tumor
- lipopeptide
- preventing
- Prior art date
Links
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 title claims abstract description 64
- 108010028921 Lipopeptides Proteins 0.000 title claims abstract description 56
- 239000000203 mixture Substances 0.000 title claims abstract description 14
- 239000002671 adjuvant Substances 0.000 title abstract description 15
- 230000001225 therapeutic effect Effects 0.000 title abstract description 8
- 238000002619 cancer immunotherapy Methods 0.000 title abstract 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims abstract description 36
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims abstract description 36
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims abstract description 36
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims abstract description 36
- 239000004480 active ingredient Substances 0.000 claims abstract description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 196
- 201000011510 cancer Diseases 0.000 claims description 78
- 239000003446 ligand Substances 0.000 claims description 44
- 102000002689 Toll-like receptor Human genes 0.000 claims description 42
- 108020000411 Toll-like receptor Proteins 0.000 claims description 42
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 238000002360 preparation method Methods 0.000 claims description 20
- 229930182490 saponin Natural products 0.000 claims description 16
- 150000007949 saponins Chemical class 0.000 claims description 16
- 235000017709 saponins Nutrition 0.000 claims description 16
- 230000028993 immune response Effects 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 abstract description 36
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 27
- 230000001093 anti-cancer Effects 0.000 abstract description 17
- 238000011319 anticancer therapy Methods 0.000 abstract description 8
- 230000007246 mechanism Effects 0.000 abstract description 6
- -1 anticancer vaccines Substances 0.000 abstract description 4
- 201000009030 Carcinoma Diseases 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 62
- 238000010172 mouse model Methods 0.000 description 46
- 206010009944 Colon cancer Diseases 0.000 description 41
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 33
- 238000010586 diagram Methods 0.000 description 23
- 230000005760 tumorsuppression Effects 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 239000013642 negative control Substances 0.000 description 19
- 239000002955 immunomodulating agent Substances 0.000 description 18
- 239000000872 buffer Substances 0.000 description 17
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 16
- 102100024333 Toll-like receptor 2 Human genes 0.000 description 16
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 15
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 15
- 210000002865 immune cell Anatomy 0.000 description 15
- 238000009169 immunotherapy Methods 0.000 description 15
- 239000000427 antigen Substances 0.000 description 14
- 102000036639 antigens Human genes 0.000 description 14
- 108091007433 antigens Proteins 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 12
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 11
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 11
- 230000008595 infiltration Effects 0.000 description 11
- 238000001764 infiltration Methods 0.000 description 11
- 102000003952 Caspase 3 Human genes 0.000 description 10
- 108090000397 Caspase 3 Proteins 0.000 description 10
- OEDPHAKKZGDBEV-GFPBKZJXSA-N (2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2r)-3-[2,3-di(hexadecanoyloxy)propylsulfanyl]-2-(hexadecanoylamino)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoyl]amino]hexanoic acid Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CCCCCCCCCCCCCCC)CSCC(COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC OEDPHAKKZGDBEV-GFPBKZJXSA-N 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 201000001441 melanoma Diseases 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 206010005003 Bladder cancer Diseases 0.000 description 8
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 8
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 8
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 8
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 8
- 208000029742 colonic neoplasm Diseases 0.000 description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 8
- 201000002528 pancreatic cancer Diseases 0.000 description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 description 8
- 201000005112 urinary bladder cancer Diseases 0.000 description 8
- 238000011740 C57BL/6 mouse Methods 0.000 description 7
- 230000006907 apoptotic process Effects 0.000 description 7
- 230000024932 T cell mediated immunity Effects 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 5
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 5
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 229960002751 imiquimod Drugs 0.000 description 5
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 5
- 230000005965 immune activity Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 230000002147 killing effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 4
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 4
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 4
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 4
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000003125 immunofluorescent labeling Methods 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 102000011727 Caspases Human genes 0.000 description 3
- 108010076667 Caspases Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000001875 tumorinhibitory effect Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000008096 B7-H1 Antigen Human genes 0.000 description 2
- 108010074708 B7-H1 Antigen Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229950002916 avelumab Drugs 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002601 intratumoral effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 229960002621 pembrolizumab Drugs 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- GGXRLUDNGFFUKI-ORGXJRBJSA-N (4s)-4-[[(2s)-2-acetamido-3-carboxypropanoyl]amino]-5-[[(2s)-1-[[(2s)-3-carboxy-1-(4-nitroanilino)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-oxopentanoic acid Chemical compound OC(=O)C[C@H](NC(C)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)NC1=CC=C([N+]([O-])=O)C=C1 GGXRLUDNGFFUKI-ORGXJRBJSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 229940124101 Caspase 3 inhibitor Drugs 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 238000011510 Elispot assay Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101001044384 Mus musculus Interferon gamma Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 1
- 230000029662 T-helper 1 type immune response Effects 0.000 description 1
- 102100039387 Toll-like receptor 6 Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108010038407 acetyl-aspartyl-glutamyl-valyl-aspartic acid p-nitroanilide Proteins 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- SQQXRXKYTKFFSM-UHFFFAOYSA-N chembl1992147 Chemical compound OC1=C(OC)C(OC)=CC=C1C1=C(C)C(C(O)=O)=NC(C=2N=C3C4=NC(C)(C)N=C4C(OC)=C(O)C3=CC=2)=C1N SQQXRXKYTKFFSM-UHFFFAOYSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229940124669 imidazoquinoline Drugs 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000037449 immunogenic cell death Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960005386 ipilimumab Drugs 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940066453 tecentriq Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940055760 yervoy Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- the present invention relates to an immunotherapeutic composition
- an immunotherapeutic composition comprising a lipopeptide and a poly(I:C) adjuvant as active ingredients.
- the present invention relates to an immunotherapeutic agent composition in which anticancer immunoactivity is increased by co-administering a lipopeptide and a poly(I:C) adjuvant with an immune checkpoint inhibitor or another TLR ligand.
- TLR Toll-like receptor
- PAMP pathogen-related molecular pattern
- TLRs known to be expressed in most immune cells are also known to be expressed in various cancer cells (Non-Patent Document 1, Cancer Microenvironment (2009) 2 (Suppl 1): S205-S214, Cancer Cells Expressing Toll-like Receptors and the Tumor Microenvironment).
- TLRs expressed in cancer cells can induce the infiltration of immune cells into cancer cells through the secretion of cytokines and chemokines in cancer cells, thereby increasing the immune response in the tumor microenvironment.
- TLR stimulators TLR ligands
- TLR ligands activate TLR stimulators
- Caspase pathway in cancer cells, thereby inducing apoptosis in cancer cells and causing cell death.
- Type I IFN activated by TLR ligand further promotes apoptosis through activation of immune cells.
- cancer cells are killed by TLR ligands, endogenous proteins and immunogenic cell death markers are secreted from dead cancer cells, and dendritic cells are activated by these factors, and cancer cell-specific NK cells and T cells become cancer cells play a role in killing
- TLR ligands are expected to be developed as immuno-anticancer agents by inducing cancer cell death and cancer antigen-specific immune responses.
- Immune checkpoint proteins are cell membrane proteins that function to inhibit the differentiation, proliferation, and activity of immune cells, but are expressed not only in immune cells but also in cancer cells.
- Immune checkpoint proteins such as PD-L1 expressed in cancer cells are known to play an important role in protecting cancer cells from immune attack by T cells by inactivating cancer-specific T cells, thereby inducing immune evasion mechanisms in cancer.
- Immune checkpoint inhibitors inhibit the function of these immune checkpoint proteins, thereby helping immune anti-cancer drugs to remove cancer cells.
- Immune checkpoint inhibitors are known to have a high therapeutic effect in about 30% of patients treated when treated alone, but have no therapeutic effect in the rest of the patients. It is known that the reason for the limited effect of immune checkpoint inhibitors is the low response rate and resistance to immune checkpoint inhibitors.
- the low response rate of immune checkpoint inhibitors shows a low response rate for carcinomas with a low expression level, as the expression level of the immune checkpoint protein varies depending on the type of carcinoma.
- the evasion mechanism is suppressed through an immune checkpoint inhibitor, the exposure of cancer antigens is low, so a cancer-specific immune response capable of killing cancer cells is not induced, resulting in a low response rate. Therefore, the limitations of immune checkpoint inhibitors can be overcome only when a method capable of increasing exposure of cancer antigens and increasing cancer-specific immune responses is used in combination.
- a method for converting a low-immunogenic tumor environment into a high-immunogenic tumor environment is required, which can be expected to be solved by enhancing immunogenicity using TLR ligands.
- the present inventors developed a vaccine composition containing a TLR2 ligand lipopeptide and a TLR3 ligand poly(I:C) in a previous study, and confirmed that the vaccine composition induced a strong immune response (Republic of Korea Patent No. 10-0900837 No., Republic of Korea Patent Registration No. 10-1501583), the vaccine composition was named L-pampo.
- L-Pampo causes a strong immuno-anticancer response
- by administering L-Pampo to tumor cells using the anti-cancer effect and cancer antigen-specific immune response induction effect due to changes in the tumor microenvironment, It was confirmed that it inhibits the growth of cancer cells, induces apoptosis, and inhibits metastasis, and when L-Pampo is administered in combination with other TLR ligands, saponin, or immune checkpoint inhibitors, it overcomes immune evasion of cancer cells and dramatically improves anticancer efficacy. By confirming that, the present invention was completed.
- An object of one aspect of the present invention is,
- compositions for preventing or treating cancer comprising a lipopeptide and a poly(I:C) adjuvant as active ingredients.
- Another object of the present invention is,
- a method for generating an immune response against cancer in a subject comprising administering a pharmaceutical composition for preventing or treating cancer containing a lipopeptide and poly(I:C) as active ingredients to a non-human subject is to provide
- Another object of the present invention is,
- Another object of the present invention is,
- It is to provide a combination preparation for preventing or treating cancer comprising a lipopeptide, a poly(I:C) adjuvant, and a TLR ligand as active ingredients.
- compositions for preventing or treating cancer comprising lipopeptide and poly(I:C) as active ingredients.
- a method for generating an immune response against cancer in a subject comprising administering a pharmaceutical composition for preventing or treating cancer containing a lipopeptide and poly(I:C) as active ingredients to a non-human subject provides
- a combined preparation for the prevention or treatment of cancer comprising a lipopeptide, a poly(I:C) adjuvant, and an immune checkpoint inhibitor as active ingredients.
- a combination preparation for preventing or treating cancer including a second component including a lipopeptide, a poly(I:C) adjuvant, and a Toll-like receptor (TLR) ligand as active ingredients.
- a second component including a lipopeptide, a poly(I:C) adjuvant, and a Toll-like receptor (TLR) ligand as active ingredients.
- TLR Toll-like receptor
- a combination preparation for preventing or treating cancer containing lipopeptide and poly(I:C) adjuvant and saponin as active ingredients.
- An immunotherapeutic agent composition comprising lipopeptide and poly(I:C) adjuvant as active ingredients provided in one aspect of the present invention can induce a high therapeutic effect on various cancer types, and is a chemical anticancer agent with a different mechanism, anticancer agent. It significantly enhances the anticancer effect through combined administration with existing anticancer drugs such as vaccines and immune checkpoint inhibitors.
- FIG. 1 is a diagram confirming the Caspase-3 activity of an immunotherapeutic agent in a mouse colon cancer cell line.
- Figure 2 is a diagram confirming the tumor suppression efficacy of immuno-anticancer therapy in a melanoma tumor mouse model.
- Figure 3 is a diagram confirming the tumor suppression efficacy of immuno-anticancer therapy in a mouse model of colorectal cancer tumor.
- FIG. 4 is a diagram illustrating the infiltration of immune cells into a tumor of an anti-cancer immunotherapeutic agent using immunofluorescence staining in a mouse model of colorectal cancer.
- FIG. 5 is a diagram illustrating the infiltration of immune cells into a tumor of an immunotherapeutic agent using a flow cytometer in a mouse model of colorectal cancer.
- FIG. 6 is a diagram illustrating the induction of a tumor-specific cellular immune response of an immunotherapeutic agent using an ELISPOT assay in a mouse model of colorectal cancer.
- Figure 7 is a diagram analyzing the abscopal efficacy of immuno-anticancer drugs in a mouse model of colorectal cancer tumors.
- Figure 8 is a diagram confirming the tumor suppression efficacy of immuno-anticancer therapy in bladder cancer mouse model.
- FIG. 9 is a diagram confirming the tumor suppression efficacy of immuno-anticancer therapeutic agents in a pancreatic cancer mouse model.
- FIG. 10 is a diagram confirming the combined efficacy of an immune checkpoint inhibitor of an immunotherapeutic agent in a mouse model of colorectal cancer.
- 11a is a diagram confirming the combination efficacy (tumor size) of an immunotherapeutic agent with another TLR ligand or saponin in a mouse model of colorectal cancer.
- Figure 11b is a diagram confirming the combination efficacy (tumor weight) of immunotherapies with other TLR ligands or saponins in a mouse model of colorectal cancer.
- compositions for preventing or treating cancer comprising lipopeptide and poly(I:C) as active ingredients.
- the lipopeptide is a synthetic analogue of a lipopeptide derived from bacteria and mycoplasma and was first synthesized by J. Metzger et al. (Metzger, J. et al ., 1991, Synthesis of novel immunologically active tripalmitoyl- S-glycerylcysteinyl lipopeptides as useful intermediates for immunogen preparations. Int. J. Peptide Protein Res. 37: 46-57).
- the molecular structure of the compound represented by the following formula (1) is N-palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-[R]-cystein-SKKKK (pam3Cys-SKKKK), in addition to Various analogues have been synthesized.
- Lipopeptides are generally known as ligands for TLR2. The use of such a lipopeptide is not limited to Pam3Cys-SKKKK, and the lipopeptide may consist of a fatty acid and several amino acids bound to a glycerol molecule.
- the number of fatty acids in a molecule can be one or more.
- the number of amino acids in a lipopeptide can be one or more.
- fatty acids and amino acids can be chemically modified.
- the lipopeptide may be a lipoprotein in the form of a whole molecule or part of a molecule derived from a gram-positive or gram-negative bacterium or mycoplasma.
- poly(I:C) has been used as a potent derivative of type 1 interferon in in vitro and in vivo studies.
- poly(I:C) is known to stably and mature dendritic cells, which are the most powerful antigen-presenting cells in mammals (Rous, R. et al 2004. poly(I:C) used for human dendritic cells). cell maturation preserves their ability to secondarily secrete bioactive Il-12, International Immunol. 16: 767-773).
- poly(I:C) is a potent IL-12 inducer, and IL-12 is an important cytokine that induces cellular immune responses and IgG2a or IgG2b antibody formation by promoting the development of Th1 immune responses.
- poly(I:C) is known to have potent adjuvant activity against peptide antigens (Cui, Z. and F. Qui. 2005. Synthetic double stranded RNA poly I:C as a potent peptide vaccine adjuvant: Therapeutic activity against human cervical cancer in a rodent model. Cancer Immunol. Immunotherapy 16: 1-13).
- Poly(I:C) is known as a representative TLR3 ligand. Poly(I:C) may range in length from 50 to 5,000 bp, preferably from 50 to 2,000 bp, preferably from 100 to 500 bp, but is not particularly limited thereto.
- the lipopeptide and poly(I:C) may be included in the pharmaceutical composition at a weight ratio of 0.1 to 10:1, a weight ratio of 1.25 to 2:1, a weight ratio of 1.25 to 1.5:1, or a weight ratio of 1.25:1, but particularly It is not limited thereto, and may be adjusted to an appropriate level according to the condition of the patient.
- the pharmaceutical composition may be an aqueous solution formulation.
- the pharmaceutical composition may further include one or more selected from the group consisting of pharmaceutically acceptable carriers, diluents and adjuvants.
- the pharmaceutical composition may include a pharmaceutically acceptable carrier, and may be formulated for human or veterinary use and administered through various routes.
- the route of administration may be oral, intraperitoneal, intravenous, intramuscular, subcutaneous, or intradermal administration. Preferably, it is formulated and administered as an injection.
- Injectables include aqueous solvents such as physiological saline and IV, vegetable oils, higher fatty acid esters (e.g., ethyl oleate, etc.), non-aqueous solvents such as alcohols (e.g., ethanol, benzyl alcohol, propylene glycol, glycerin, etc.), etc. It can be manufactured using a stabilizer (e.g., ascorbic acid, sodium hydrogen sulfite, sodium pyrosulfite, BHA, tocopherol, EDTA, etc.) to prevent deterioration, an emulsifier, a buffer to control pH, and to inhibit the growth of microorganisms.
- a stabilizer e.g., ascorbic acid, sodium hydrogen sulfite, sodium pyrosulfite, BHA, tocopherol, EDTA, etc.
- the pharmaceutical composition may be administered in a pharmaceutically effective amount.
- pharmaceutically effective amount refers to an amount sufficient to exhibit an immuno-anticancer effect and an amount sufficient to not cause side effects or severe or excessive immune reactions, and the exact dosage concentration varies depending on the composition to be administered, and the patient It can be easily determined by a person skilled in the art according to factors well known in the medical field, such as age, weight, health, sex, sensitivity to a drug of a patient, route of administration, and method of administration, and can be administered once or several times.
- Another aspect of the present invention is,
- a method for generating an immune response against cancer in a subject comprising administering a pharmaceutical composition for preventing or treating cancer containing a lipopeptide and poly(I:C) as active ingredients to a non-human subject provides
- the pharmaceutical composition is administered to a human (patient), it can be administered in an amount effective to stimulate an immune response in vivo, for example, it can be administered to humans once or several times, and the dosage is 0.25 It may be -3.6 mg, more preferably 0.45-1.8 mg, but is not particularly limited thereto.
- Another aspect of the present invention is,
- a pharmaceutical combination preparation for preventing or treating cancer including lipopeptide and poly(I:C) and an immune checkpoint inhibitor as active ingredients.
- At least one selected from the group consisting of an anti-CTLA4 antibody, an anti-PD-L1 antibody, and an anti-PD-1 antibody may be used.
- the immune checkpoint inhibitor is an anti-CTLA4 antibody, a derivative thereof or an antigen-binding fragment thereof; an anti-PD-L1 antibody, derivative thereof or antigen-binding fragment thereof; anti-LAG-3 antibodies, derivatives or antigen-binding fragments thereof; an anti-OX40 antibody, derivative thereof or antigen-binding fragment thereof; an anti-TIM3 antibody, derivative thereof or antigen-binding fragment thereof; and anti-PD-1 antibodies, derivatives thereof, or antigen-binding fragments thereof.
- an immune checkpoint inhibitor targeting CTLA-4 may use Yervoy (ipilimumab);
- Immune checkpoint inhibitors targeting PD-L1 include Tecentriq (atezolizumab), Avelumab (Bavencio), and Imfinzi (Durvalumab), either alone or in combination of two or more. available;
- Immune checkpoint inhibitors targeting PD-1 include Keytruda (Pembrolizumab), Opdivo (Nivolumab), and Libtayo (Semiplimab) alone or in combination of two or more. and can be used.
- Another aspect of the present invention is,
- a combination preparation for preventing or treating cancer including a lipopeptide and poly(I:C) and a Toll-like receptor (TLR) ligand as active ingredients.
- TLR Toll-like receptor
- TLR7 ligands Imiquimod, etc.
- TLR7/8 ligands Imidazoquinoline, etc.
- TLR9 ligands CpG ODN, etc.
- Another aspect of the present invention is,
- a combination preparation for preventing or treating cancer containing lipopeptide and poly(I:C) and saponin as active ingredients.
- the saponin may be selected from the group consisting of QS21, Quil A, QS7, QS17, and combinations thereof.
- An immunotherapeutic agent composition comprising lipopeptide and poly(I:C) adjuvant as active ingredients provided in one aspect of the present invention can induce a high therapeutic effect on various cancer types, and is a chemical anticancer agent with a different mechanism, anticancer agent. It significantly enhances the anticancer effect through combined administration with existing anticancer drugs such as vaccines and immune checkpoint inhibitors.
- the immuno-anticancer composition (hereinafter referred to as L-pampo) comprising the lipopeptide and poly(I:C) of the present invention is a caspase in cancer cells, more than when the lipopeptide or poly(I:C) is treated alone. It was confirmed that apoptosis of cancer cells could be induced by further activating Caspase-3 of the first pathway (see FIG. 1). Accordingly, it was confirmed that L-pampo most strongly induces apoptosis of colon cancer cells.
- L-pampo reduced the size of tumors in the melanoma mouse model (see FIG. 2), and it was confirmed that L-pampo reduced the size of tumors in the colorectal cancer mouse model, indicating that it has anticancer efficacy. could (see Figure 3).
- the L-pampo of the present invention induces the infiltration of many CD8 T cells into the tumor of the colorectal cancer mouse model and suppresses Treg+ cells, thereby inducing immune activity capable of killing the tumor (FIG. 4 and FIG. see 5).
- the L-pampo of the present invention strongly induces a tumor-specific cellular immune response by increasing the secretion of IFN- ⁇ in a mouse model of colorectal cancer (see FIG. 6).
- the L-pampo of the present invention has an abscopal effect of reducing the size of not only tumors to which L-pampo was administered but also to tumors to which L-pampo was not administered (see FIG. 7).
- L-pampo reduced the size of tumors in a mouse model of bladder cancer (see FIG. 8), and it was confirmed that L-pampo also reduced the size of tumors in a mouse model of pancreatic cancer (see FIG. 9).
- the above results suggest that the L-pampo of the present invention exhibits anticancer efficacy in various cancers.
- L-pampo containing the lipopeptide and poly(I:C) of the present invention induces a cancer-specific cellular immune response, infiltrates many CD8+ T cells into tumors, and has strong anti-cancer effects that strongly inhibit tumor growth.
- intratumoral administration of the immuno-anticancer composition containing L-pampo kills cancer cells and can be used as an immuno-anticancer agent showing strong anti-cancer efficacy through cancer-specific immune response and infiltration of immune cells into tumors.
- Colon cancer cell line MC38 cells were seeded in a 12-well culture plate at 1.5 ⁇ 10 5 cells/well, and the next day, TLR2 ligand (Pam3CSK4), TLR3 ligand (Poly (I:C)), or TLR2 (Pam3CSK4) and TLR3 ligand ( After treatment with L-pampo mixed with Poly(I:C)), it was cultured for 24 hours. At this time, L-pampo was prepared by mixing 50 ⁇ g of TLR2 ligand (Pam3CSK4) and 40 ⁇ g of TLR3 ligand (Poly(I:C)).
- the cells were recovered, resuspended in about 100 ⁇ L of lysis buffer, and incubated on ice for 5 minutes. After centrifugation at 1000 x g for 10 minutes at 4°C, the lysate of the supernatant was taken and transferred to a new e-tube. After measuring the concentration of each sample through BCA analysis, adjust the concentration of all samples equally. These cell extract samples are stored at 4°C for immediate use and at -20°C for long-term storage.
- the assay was performed according to the instructions of the caspase-3 cell activity assay kit (Millipore, #235419). Blank, negative control (caspase-3 inhibitor-treated cell extract), positive control (purified caspase-3), and cell extract of each sample were reacted with caspase substrate (Ac-DEVD-pNA) for a minimum of 30 minutes to a maximum For 120 minutes, the O.D. (405 nm) value was measured through color development at intervals of 5 to 10 minutes. Through the substrate standard, the conversion factor is calculated and the activity of each sample is expressed in terms of p mol/min.
- caspase-3 The activity of caspase-3 was compared and analyzed in the negative and positive control groups and cell extract samples treated with TLR2 ligand, TLR3 ligand, and L-pampo.
- Figure 1 is a diagram confirming the Caspase-3 activity of an immunotherapeutic agent in a mouse colon cancer cell line.
- L-pampo is a colorectal cancer cell line MC38 It was confirmed that apoptosis was most strongly induced in cells.
- L-pampo an immuno-anticancer drug
- a buffer administration group was set as a negative control group, and when the tumor size of the melanoma tumor mouse model constructed in [2-1] reached about 100 mm 3 , 90 ⁇ g/dose of L-pampo was injected into the tumor at 3-day intervals. was administered 3 times.
- Tumor sizes of all experimental groups were measured every 2 to 3 days.
- the long and short axes of the tumor were measured, and the size of the tumor was calculated as [1/2 ⁇ long axis size ⁇ (short axis size) 2 ].
- the tumor suppression efficacy of the immunotherapy agent was analyzed.
- Figure 2 is a diagram confirming the tumor suppression efficacy of immuno-anticancer therapy in a melanoma tumor mouse model.
- test group administered with the immuno-anticancer drug L-pampo suppressed the tumor size by about 52.8% on D22, 12 days after the start of administration, compared to the buffer test group, which is a negative control group. It was confirmed that L-pampo has melanoma tumor suppression effect.
- mice 7-week-old female C57BL/6 mice (Orient Bio, Korea) were subcutaneously injected with 5 ⁇ 10 4 MC38 mouse colorectal cancer cell line into the right flank to generate tumors in the mice.
- L-pampo an immuno-anticancer drug
- a buffer administration group was set as a negative control group.
- the tumor size of all experimental groups was measured every 3 days.
- the long and short axes of the tumor were measured, and the size of the tumor was calculated as [1/2 ⁇ long axis size ⁇ (short axis size) 2 ].
- the tumor suppression efficacy of the immunotherapy agent was analyzed.
- Figure 3 is a diagram confirming the tumor suppression efficacy of immuno-anticancer therapy in a mouse model of colorectal cancer tumor.
- the D19 L-pampo test group 12 days after the start of administration, showed a strong level of anticancer efficacy with 85.2% tumor suppression. This shows that the immuno-anticancer drug L-pampo can strongly inhibit the growth of colorectal cancer tumors.
- mice tumors collected were fixed in 1% paraformaldehyde and then dehydrated using a 20% sucrose solution.
- the tumor tissue was frozen in an optimal cutting temperature (OCT) compound, and the frozen tumor tissue was cut to a thickness of 50 ⁇ m using a cryotome and fixed to a slide.
- OCT optimal cutting temperature
- the tumor tissue fixed on the slide was reacted with a blocking solution for 1 hour.
- the CD8 antibody and the CD31 antibody were diluted 1:200 and reacted at 4°C for 24 hours.
- the fluorescent antibody and DAPI solution were reacted at room temperature for 2 hours.
- fluorescence images were analyzed using a confocal microscope.
- FIG. 4 is a diagram illustrating the infiltration of immune cells into a tumor of an anti-cancer immunotherapeutic agent using immunofluorescence staining in a mouse model of colorectal cancer.
- the L-pampo test group showed that significantly more CD8 T cells (green fluorescence) were infiltrated into the tumor than the CD8+ T cells infiltrated in the negative control buffer test group. This shows that L-pampo can induce tumor suppression effect by immune cells by inducing the infiltration of many CD8 T cells into the tumor.
- Mouse tumors collected for flow cytometry were cut into small pieces, treated with collagenase D and DNase I, and reacted at 37° C. for 1 hour. Filtered with a 70 ⁇ m cell strainer, lysed red blood cells, and then filtered again with a nylon mesh. The single cell suspension was blocked with CD16/32 antibody and then stained with cell viable dye. After staining with fluorescent dyes such as CD45, CD3, CD8, CD4, Foxp3, and CD25, the cells were measured using a CytoFLEX flow cytometer. The measured results were quantitatively compared and analyzed using FlowJo software.
- FIG. 5 is a diagram illustrating the infiltration of immune cells into a tumor of an immunotherapeutic agent using a flow cytometer in a mouse model of colorectal cancer.
- the L-pampo test group had a lot of CD8+ T cells infiltrated into the tumor.
- the number of Treg+ cells suppressing the activity of T cells in the tumor was significantly lower than that of the negative control group. This shows that L-pampo can induce immune activity capable of killing tumors by infiltrating many CD8+ T cells into tumors and suppressing Treg+ cells.
- mice On D19, 12 days after the start of administration, the spleens of all mice were collected and tumor-specific immune activity was analyzed by ELISPOT analysis.
- the collected spleen was ground in a cell strainer, and then spleen cells were isolated and dead cells were removed.
- Splenocytes and MC39 colon cancer cells were mixed and cultured in a 10:1 ratio in a 96-well plate encoded with mouse IFN- ⁇ . After incubation with detection antibody for 2 hours at room temperature, it was incubated with streptavidin-ALP for 1 hour at room temperature. After incubation, a substrate solution was added to confirm the spot. Spots were analyzed using Image J software.
- FIG. 6 is a diagram illustrating the induction of tumor-specific cellular immune responses of immuno-anticancer therapeutics using ELIPOT analysis in a mouse model of colorectal cancer.
- 5 ⁇ 10 4 MC38 mouse colon cancer cell line was subcutaneously injected into the right flank of 7-week-old female C57BL/6 mice (Orient Bio, Korea), and 4 days later, 5 ⁇ 10 4 MC38 colon cancer cell line was injected into the right flank. Subcutaneous injection was performed on the left flank to form tumors on both sides. 180 ⁇ g/dose of L-pampo prepared in [3-2] was administered only to the tumor generated on the right side. The size of the tumors generated on both sides was measured every 3 days to analyze the tumor suppression efficacy.
- Figure 7 is a diagram analyzing the abscopal efficacy of immuno-anticancer drugs in a mouse model of colorectal cancer tumors.
- the L-pampo test group significantly reduced the size of tumors (right side) to which L-pampo was administered, as well as tumors (left side) to which the immuno-anticancer drug was not administered (left side). showed that it did. From this, it was confirmed that when L-pampo, an immuno-anticancer drug, is administered to tumors, L-pampo not only kills cancer cells but also induces strong tumor-specific immune activity, thereby killing tumors not administered with L-pampo. It shows that immuno-anticancer drug L-pampo can treat metastasized cancer cells.
- 5 ⁇ 10 5 MB49 mouse bladder cancer cell line was subcutaneously injected into the right flank of 7-week-old female C57BL/6 mice (Orient Bio, Korea) to generate tumors in the mice.
- L-pampo an immuno-anticancer drug
- a buffer administration group was set as a negative control group, and when the tumor size of the bladder cancer mouse model constructed in [4-1] reached about 50 mm 3 , 180 ⁇ g/dose of L-pampo was injected into the tumor 4 times at 3-day intervals. administered.
- the tumor size of all experimental groups was measured every 3 days.
- the long and short axes of the tumor were measured, and the size of the tumor was calculated as [1/2 ⁇ long axis size ⁇ (short axis size) 2 ].
- the tumor suppression efficacy of the immunotherapy agent was analyzed.
- Figure 8 is a diagram confirming the tumor suppression efficacy of immuno-anticancer therapy in bladder cancer mouse model.
- the test group administered with the immuno-anticancer drug L-pampo was confirmed to suppress the size of tumors by about 60.3% on D24, 18 days after the start of administration, compared to the buffer test group, which is a negative control group. It was confirmed that L-pampo can strongly inhibit the growth of bladder cancer.
- 5 ⁇ 10 5 KPC mouse pancreatic cancer cell line was subcutaneously injected into the right flank of 8-week-old female C57BL/6 mice (Orient Bio, Korea) to generate tumors in the mice.
- L-pampo an immuno-anticancer drug
- a buffer administration group was set as a negative control group, and when the tumor size of the pancreatic cancer mouse model constructed in [5-1] reached about 50 mm 3 , 180 ⁇ g/dose of L-pampo was injected into the tumor 4 times at 3-day intervals. administered.
- the tumor size of all experimental groups was measured every 3 days.
- the long and short axes of the tumor were measured, and the size of the tumor was calculated as [1/2 ⁇ long axis size ⁇ (short axis size) 2 ].
- the tumor suppression efficacy of the immunotherapy agent was analyzed.
- FIG. 9 is a diagram confirming the tumor suppression efficacy of immuno-anticancer therapeutic agents in a pancreatic cancer mouse model.
- the test group administered with immuno-anticancer drug L-pampo showed a reduction in tumor size by about 82.9% on D21, 13 days after the start of administration, compared to the buffer test group, which is a negative control group. It was confirmed that pampo can strongly inhibit the growth of pancreatic cancer.
- mice 8-week-old female C57BL/6 mice (Orient Bio, Korea) were subcutaneously injected with 1 ⁇ 10 5 MC38 mouse colorectal cancer cell line into the right flank to generate tumors in the mice.
- L-pampo an immuno-anticancer drug.
- a buffer administration group was set as a negative control group, and when the tumor size of the colorectal cancer mouse model constructed in [6-1] reached about 50 mm 3 , 50 ⁇ g/dose of L-pampo was injected into the tumor every 3 days for 4 administered twice.
- Mouse PD-1 antibody an immune checkpoint inhibitor, was purchased from BioXCell.
- a mouse PD-1 antibody monotherapy group was set as a combination control group, and 200 ⁇ g/dose of mouse PD-1 antibody was intraperitoneally administered 4 times at 3-day intervals when L-pampo was administered intratumorally.
- the tumor size of all experimental groups was measured every 3 days.
- the long and short axes of the tumor were measured, and the size of the tumor was calculated as [1/2 ⁇ long axis size ⁇ (short axis size) 2 ].
- Tumor suppression efficacy was analyzed through the calculated tumor size.
- FIG. 10 is a diagram confirming the combined efficacy of an immune checkpoint inhibitor of an immunotherapeutic agent in a mouse model of colorectal cancer.
- the test group administered with the PD-1 antibody suppressed the tumor size by about 19.2% on D19, 12 days after the start of administration, compared to the negative control buffer test group.
- the test group administered with immuno-anticancer drug L-pampo about 60.3% reduction in tumor size was confirmed on D19, showing a stronger tumor suppression effect than PD-1 antibody, an immune checkpoint inhibitor.
- the tumor size was reduced by about 80.7% on D19, and it was confirmed that the tumor disappeared completely in 1 of 8 animals. It was confirmed that the combined treatment of L-pampo and immune checkpoint inhibitors can show strong anticancer efficacy.
- mice 8-week-old female C57BL/6 mice (Orient Bio, Korea) were subcutaneously injected with 1 ⁇ 10 5 MC38 mouse colorectal cancer cell line into the right flank to generate tumors in the mice.
- L-pampo an immuno-anticancer drug
- a buffer administration group was set as a negative control group, and when the tumor size of the colorectal cancer mouse model constructed in [7-1] reached about 50 mm 3 , 45 ⁇ g/dose of L-pampo was injected into the tumor every 3 days for 4 administered twice.
- the tumor size of all experimental groups was measured every 3 days.
- the long and short axes of the tumor were measured, and the size of the tumor was calculated as [1/2 ⁇ long axis size ⁇ (short axis size) 2 ].
- Tumor suppression efficacy was analyzed through the calculated tumor size.
- FIG. 11 is a diagram confirming the combined efficacy of immunotherapies with other TLR ligands or saponins in a mouse model of colorectal cancer.
- the test group administered with another TLR ligand, imiquimod (TLR 7 ligand), showed suppression of tumor size by about 39% on D20, 12 days after the start of administration, compared to the negative control buffer test group. . Also, in the test group administered with saponin, QS-21, it was confirmed that about 57% of the tumor size was suppressed on D20. On the other hand, the L-pampo-administered test group showed the strongest tumor growth inhibitory effect among the single-administered groups by confirming a reduction in tumor size by about 78% on D20.
- the tumor size was reduced by about 84% or more on D20 in all experimental groups in which the immuno-anticancer drugs L-pampo, imiquimod, or QS-21 were administered in combination.
- the results of measuring the tumor weight of each test group on D20 also confirmed a similar trend to tumor size inhibition. It was confirmed that it can show an effect and show a strong anticancer effect.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Type of cancer | TLR |
Gastric cancer | TLR2, TLR4, TLR5, TLR9 |
Colorectal cancer | TLR2, TLR3, TLR4, TLR5, TLR9 |
Ovarian cancer | TLR2, TLR3, TLR4, TLR5 |
Cervical cancer | TLR3, TLR4, TLR5, TLR9 |
Lung cancer | TLR2, TLR3, TLR4, TLR9 |
Prostate cancer | TLR4, TLR9 |
Melanomas | TLR2, TLR3, TLR4 |
Brain cancer | TLR2, TLR4 |
Brest cancer | TLR2, TLR3, TLR4, TLR9 |
Hepatocellular carcinoma | TLR2, TLR3, TLR4, TLR6, TLR9 |
Laryngeal cancer | TLR2, TLR3, TLR4 |
Claims (20)
- 리포펩타이드 및 폴리(I:C)를 유효성분으로 포함하는 암의 예방 또는 치료용 약제학적 조성물.
- 제1항에 있어서,상기 약제학적 조성물은 T세포 면역반응 활성화를 통해 암을 예방 또는 치료하는 것을 특징으로 하는 약제학적 조성물.
- 제1항에 있어서,상기 리포펩타이드는,Pam3Cys-SKKKK, PHC-SKKKK, Ole2PamCys-SKKKK, Pam2Cys-SKKKK, PamCys(Pam)-SKKKK, Ole2Cys-SKKKK, Myr2Cys-SKKKK, PamDhc-SKKKK, PamCSKKKK 및 Dhc-SKKKK로 이루어진 군으로부터 선택되는 1종 이상인 것을 특징으로 하는 약제학적 조성물.
- 제1항에 있어서,상기 리포펩타이드 및 폴리(I:C)는 0.1 내지 10 : 1의 중량비인 것을 특징으로 하는 약제학적 조성물.
- 제1항에 있어서,상기 약제학적 조성물은 수용액 제형인 것을 특징으로 하는 약제학적 조성물.
- 리포펩타이드 및 폴리(I:C)를 유효성분으로 포함하는 암의 예방 또는 치료용 약제학적 조성물을, 인간을 제외한 개체에 투여하는 단계를 포함하는, 상기 개체에서 암에 대한 면역 반응을 생성하는 방법.
- 리포펩타이드 및 폴리(I:C) 및면역관문억제제를 유효성분으로 포함하는, 암의 예방 또는 치료용 약제학적 병용제제.
- 제7항에 있어서,상기 면역관문억제제는,항-CTLA4 항체, 항-PD-L1 항체 및 항-PD-1 항체로 이루어진 군으로부터 선택되는 하나 이상인 것을 특징으로 하는 병용제제.
- 리포펩타이드 및 폴리(I:C) 및TLR(Toll-like receptor) 리간드를 유효성분으로 포함하는, 암의 예방 또는 치료용 병용제제.
- 제9항에 있어서,상기 TLR(Toll-like receptor) 리간드는 TLR 1 내지 13으로부터 선택되는 하나 이상의 리간드인 것을 특징으로 하는 병용제제.
- 리포펩타이드 및 폴리(I:C) 및사포닌을 유효성분으로 포함하는, 암의 예방 또는 치료용 병용제제.
- 제11항에 있어서,상기 사포닌은 QS21, Quil A, QS7, QS17 및 이들의 조합들로 이루어진 군으로부터 선택되는 것을 특징으로 하는 병용제제.
- 리포펩타이드 및 폴리(I:C)를 개체에 투여하는 단계를 포함하는 암을 예방 또는 치료하는 방법.
- 리포펩타이드, 폴리(I:C) 및 면역관문억제제를 개체에 투여하는 단계를 포함하는 암을 예방 또는 치료하는 방법.
- 리포펩타이드, 폴리(I:C) 및 TLR(Toll-like receptor) 리간드를 개체에 투여하는 단계를 포함하는 암을 예방 또는 치료하는 방법.
- 리포펩타이드, 폴리(I:C) 및 사포닌을 개체에 투여하는 단계를 포함하는 암을 예방 또는 치료하는 방법.
- 암의 예방, 개선 또는 치료를 위한 약제의 제조에 사용하기 위한 리포펩타이드 및 폴리(I:C)의 용도.
- 암의 예방, 개선 또는 치료를 위한 약제의 제조에 사용하기 위한 리포펩타이드, 폴리(I:C) 및 면역관문억제제의 용도.
- 암의 예방, 개선 또는 치료를 위한 약제의 제조에 사용하기 위한 리포펩타이드, 폴리(I:C) 및 TLR(Toll-like receptor) 리간드의 용도.
- 암의 예방, 개선 또는 치료를 위한 약제의 제조에 사용하기 위한 리포펩타이드, 폴리(I:C) 및 사포닌의 용도.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280037756.6A CN117377486A (zh) | 2021-05-24 | 2022-05-24 | 采用包括脂肽和聚 (i∶c)的佐剂的免疫肿瘤学治疗组合物 |
JP2023572084A JP2024518638A (ja) | 2021-05-24 | 2022-05-24 | リポペプチド及びポリ(i:c)を含むアジュバントを使用したがん免疫療法組成物 |
CA3221194A CA3221194A1 (en) | 2021-05-24 | 2022-05-24 | Immuno-oncology therapeutic composition using adjuvant including lipopeptides and poly (i:c) |
MX2023013845A MX2023013845A (es) | 2021-05-24 | 2022-05-24 | Composicion terapeutica para inmunooncologia usando un adyuvante que incluye lipopeptidos y acido poliinosinico:policitidilico (poli (i:c)). |
BR112023024392A BR112023024392A2 (pt) | 2021-05-24 | 2022-05-24 | Uso de uma formulação de combinação farmacêutica, uso de lipopeptídeos e poli(i:c), e pelo menos um ingrediente ativo adicional |
EP22811609.1A EP4327821A1 (en) | 2021-05-24 | 2022-05-24 | Immuno-oncology therapeutic composition using adjuvant including lipopeptides and poly (i:c) |
AU2022279856A AU2022279856A1 (en) | 2021-05-24 | 2022-05-24 | Immuno-oncology therapeutic composition using adjuvant including lipopeptides and poly (i:c) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0065980 | 2021-05-24 | ||
KR20210065980 | 2021-05-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022250416A1 true WO2022250416A1 (ko) | 2022-12-01 |
Family
ID=84229339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/007348 WO2022250416A1 (ko) | 2021-05-24 | 2022-05-24 | 리포펩타이드와 폴리(i:c) 아쥬번트를 이용하는 면역항암치료제 조성물 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4327821A1 (ko) |
JP (1) | JP2024518638A (ko) |
KR (1) | KR20220158640A (ko) |
CN (1) | CN117377486A (ko) |
AU (1) | AU2022279856A1 (ko) |
BR (1) | BR112023024392A2 (ko) |
CA (1) | CA3221194A1 (ko) |
MX (1) | MX2023013845A (ko) |
WO (1) | WO2022250416A1 (ko) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100900837B1 (ko) | 2007-12-07 | 2009-06-04 | (주)두비엘 | 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물 |
KR20140119362A (ko) * | 2013-03-29 | 2014-10-10 | 주식회사 차백신연구소 | 리포펩티드 및 폴리(i:c)를 포함하는 아쥬반트 및 이를 이용한 개선된 제형의 백신 조성물 |
KR20160055861A (ko) * | 2013-09-17 | 2016-05-18 | 오비아이 파머 인코퍼레이티드 | 암치료에서 면역반응을 유도하기 위한 탄수화물 백신의 조성물 |
KR20160068751A (ko) * | 2013-08-28 | 2016-06-15 | 피씨아이 바이오테크 에이에스 | 백신접종 및 면역화를 위한 화합물 및 방법 |
KR20190018998A (ko) * | 2017-08-16 | 2019-02-26 | 주식회사 차백신연구소 | 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도 |
-
2022
- 2022-05-24 EP EP22811609.1A patent/EP4327821A1/en active Pending
- 2022-05-24 MX MX2023013845A patent/MX2023013845A/es unknown
- 2022-05-24 CN CN202280037756.6A patent/CN117377486A/zh active Pending
- 2022-05-24 AU AU2022279856A patent/AU2022279856A1/en active Pending
- 2022-05-24 BR BR112023024392A patent/BR112023024392A2/pt unknown
- 2022-05-24 WO PCT/KR2022/007348 patent/WO2022250416A1/ko active Application Filing
- 2022-05-24 KR KR1020220063211A patent/KR20220158640A/ko unknown
- 2022-05-24 CA CA3221194A patent/CA3221194A1/en active Pending
- 2022-05-24 JP JP2023572084A patent/JP2024518638A/ja active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100900837B1 (ko) | 2007-12-07 | 2009-06-04 | (주)두비엘 | 리포펩타이드와 폴리(i:c)를 아쥬반트로 포함하는 강력한백신 조성물 |
KR20140119362A (ko) * | 2013-03-29 | 2014-10-10 | 주식회사 차백신연구소 | 리포펩티드 및 폴리(i:c)를 포함하는 아쥬반트 및 이를 이용한 개선된 제형의 백신 조성물 |
KR101501583B1 (ko) | 2013-03-29 | 2015-03-12 | 주식회사 차백신연구소 | 리포펩티드 및 폴리(i:c)를 포함하는 아쥬반트 및 이를 이용한 개선된 제형의 백신 조성물 |
KR20160068751A (ko) * | 2013-08-28 | 2016-06-15 | 피씨아이 바이오테크 에이에스 | 백신접종 및 면역화를 위한 화합물 및 방법 |
KR20160055861A (ko) * | 2013-09-17 | 2016-05-18 | 오비아이 파머 인코퍼레이티드 | 암치료에서 면역반응을 유도하기 위한 탄수화물 백신의 조성물 |
KR20190018998A (ko) * | 2017-08-16 | 2019-02-26 | 주식회사 차백신연구소 | 리포펩티드가 삽입된 리포좀을 유효성분으로 포함하는 백신 아쥬반트 및 이의 용도 |
Non-Patent Citations (3)
Title |
---|
CUI, Z.F. QUI: "Synthetic double stranded RNA poly I:C as a potent peptide vaccine adjuvant: Therapeutic activity against human cervical cancer in a rodent model", CANCER IMMUNOL. IMMUNOTHERAPY, vol. 16, 2005, pages 1 - 13 |
METZGER, J. ET AL.: "Synthesis of novel immunologically active tripalmitoyl-S-glycerylcysteinyllipopeptides as useful intermediates for immunogen preparations", INT. J. PEPTIDE PROTEIN RES., vol. 37, 1991, pages 46 - 57, XP000471627 |
ROUS, R. ET AL.: "poly(I:C) used for human dendritic cell maturation preserves their ability to secondarily secrete bioactive 11-12", INTERNATIONAL IMMUNOL., vol. 16, 2004, pages 767 - 773 |
Also Published As
Publication number | Publication date |
---|---|
CA3221194A1 (en) | 2022-12-01 |
EP4327821A1 (en) | 2024-02-28 |
AU2022279856A1 (en) | 2023-12-14 |
JP2024518638A (ja) | 2024-05-01 |
MX2023013845A (es) | 2023-12-08 |
BR112023024392A2 (pt) | 2024-02-15 |
CN117377486A (zh) | 2024-01-09 |
KR20220158640A (ko) | 2022-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018097540A2 (ko) | 무혈청면역세포배양용 배지첨가키트, 상기 키트를 이용한 면역세포배양방법, 상기 키트 또는 배양방법에 의해 얻어진 무혈청면역세포배양액 및 상기 배양액을 포함하는 화장료조성물 | |
WO2015093854A1 (ko) | 전립선 암 치료용 조성물 | |
WO2017095191A1 (ko) | 면역글로불린 fc가 융합된 인터루킨-7 융합 단백질을 포함하는 사람 파필로마바이러스 유래 질환의 예방 또는 치료용 약학적 조성물 | |
EP4143207A1 (en) | Vaccine composition for preventing or treating infection of sars-cov-2 | |
US9221876B2 (en) | Methods for treating kidney disease with fragments of ApoB-100 | |
WO2020059895A1 (ko) | 스팅 작용자를 포함하는 면역항원보강제 및 백신 조성물 | |
WO2020162705A1 (ko) | 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도 | |
WO2015167243A1 (ko) | 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도 | |
WO2019039700A1 (ko) | 멜리틴을 포함하는 m2형 종양관련 대식세포 제거용 조성물 | |
WO2022250416A1 (ko) | 리포펩타이드와 폴리(i:c) 아쥬번트를 이용하는 면역항암치료제 조성물 | |
WO2021040064A1 (ko) | 백시니아 바이러스 및 히드록시유레아를 유효성분으로 포함하는 암 치료용 약학 조성물 | |
WO2019088590A2 (ko) | 마이코박테리움 파라고르도네의 항암 면역치료법 용도 | |
WO2023055078A1 (ko) | Hsp90 항원성 펩타이드를 포함하는 항암용 백신 조성물 및 이의 용도 | |
WO2022131820A1 (ko) | 아토피 피부염 예방 또는 치료용 항염증 펩타이드 | |
WO2022108306A1 (ko) | 인터류킨-33을 처리하여 면역원성이 향상된 cd103+ fcgr3+ 수지상세포의 제조방법 및 상기 수지상세포를 포함하는 면역항암치료용 약학적 조성물 | |
WO2022108094A1 (ko) | 경구용 항바이러스제 및 리포펩타이드와 폴리(i:c) 아쥬반트를 포함한 치료백신을 유효성분으로 포함하는 만성 b형 간염의 예방 또는 치료용 약제학적 조성물, 약제학적 병용제제, 병용제 키트 | |
WO2021251790A1 (ko) | 항비만 활성을 가지는 디옥시콜산-펩타이드 결합체 및 이의 용도 | |
WO2015023147A1 (ko) | mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽 줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물 | |
WO2018147612A1 (ko) | 암의 전이 억제 및 치료용 조성물 | |
WO2023146008A1 (ko) | 알로페론으로 배양된 nk 세포를 함유하는 암 예방 또는 치료용 조성물 | |
WO2014193060A1 (ko) | 인간골수유래 중간엽줄기세포와 미노사이클린 병용투여를 통한 다발성경화증 치료제 및 치료방법 | |
WO2023128378A1 (ko) | K-ras 특이적 활성화 t 세포를 포함하는 대장암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 | |
WO2023128379A1 (ko) | K-ras 특이적 활성화 t 세포를 포함하는 유방암의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 | |
WO2023128377A1 (ko) | K-ras 특이적 활성화 t 세포를 포함하는 폐 유두상 선암종의 예방 및 치료용 약제학적 조성물 및 이의 제조방법 | |
WO2022035247A1 (ko) | B형 간염 바이러스 유래 폴리펩티드를 포함하는 암의 예방 또는 치료용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22811609 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 18563350 Country of ref document: US Ref document number: 2023572084 Country of ref document: JP Ref document number: 3221194 Country of ref document: CA Ref document number: 805711 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2023/013845 Country of ref document: MX Ref document number: 2022279856 Country of ref document: AU Ref document number: AU2022279856 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280037756.6 Country of ref document: CN Ref document number: 2022811609 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2022811609 Country of ref document: EP Effective date: 20231124 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023024392 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2022279856 Country of ref document: AU Date of ref document: 20220524 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023131041 Country of ref document: RU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 112023024392 Country of ref document: BR Kind code of ref document: A2 Effective date: 20231122 |